Paris — May 26, 2026 — Median Technologies, a global leader in AI‑powered medical imaging, has launched a €40 million capital increase, with a potential upsize to €50 million, to support the rollout of its proprietary Eyonis LCS platform in the United States and Europe. The funding will also advance new clinical indications for the Eyonis technology, reinforcing the company’s commitment to innovation in precision oncology.
The capital raise will strengthen Median’s ability to scale its AI‑driven lung cancer screening solution and expand collaborations with hospitals and research institutions. The company aims to accelerate regulatory approvals and broaden the clinical reach of Eyonis, which integrates artificial intelligence with imaging to improve early cancer detection and patient outcomes.
Median Technologies’ leadership highlighted that this investment marks a pivotal step toward making AI‑enabled imaging a standard in cancer care. The initiative reflects growing investor confidence in the health‑tech sector, where AI continues to transform diagnostics and treatment planning.
Analysts view the move as a strategic milestone for the European med‑tech industry, signaling resilience and growth amid global market challenges. With this capital increase, Median Technologies is poised to expand its footprint and drive the next phase of innovation in medical imaging and oncology
